Evidence map›Paper›PMID 42170034›Full record

ArticleKidney international reports2026

Reappraisal of Risk Factors for T-Cell-Mediated Kidney Rejection.

Michiel G H Betjes, Judith A Kal-van Gestel, Nicolle H R Litjens, Marcia M L Kho, Jacqueline van de Wetering, Marc H Hemmelder, Annelies E de Weerd

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Michiel G H BetjesDivision of Nephrology and Transplantation, Department of Internal Medicine, Erasmus Medical Center Transplant Institute, University Medical Center, Rotterdam, The Netherlands.
Judith A Kal-van GestelDivision of Nephrology and Transplantation, Department of Internal Medicine, Erasmus Medical Center Transplant Institute, University Medical Center, Rotterdam, The Netherlands.
Nicolle H R LitjensDivision of Nephrology and Transplantation, Department of Internal Medicine, Erasmus Medical Center Transplant Institute, University Medical Center, Rotterdam, The Netherlands.
Marcia M L KhoDivision of Nephrology and Transplantation, Department of Internal Medicine, Erasmus Medical Center Transplant Institute, University Medical Center, Rotterdam, The Netherlands.
Jacqueline van de WeteringDivision of Nephrology and Transplantation, Department of Internal Medicine, Erasmus Medical Center Transplant Institute, University Medical Center, Rotterdam, The Netherlands.
Marc H HemmelderDivision of Nephrology and Transplantation, Department of Internal Medicine, Erasmus Medical Center Transplant Institute, University Medical Center, Rotterdam, The Netherlands.
Annelies E de WeerdDivision of Nephrology and Transplantation, Department of Internal Medicine, Erasmus Medical Center Transplant Institute, University Medical Center, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The risk factors for and the impact of T-cell-mediated rejection (TCMR) in the long term after kidney transplantation in recipients receiving anti-cluster of differentiation (CD)25 induction, followed by tacrolimus or mycophenolate mofetil (MMF) or prednisone maintenance is unknown. Methods: A single center cohort of 2024 kidney transplant recipients between 2010 and 2020 with follow-up until June 2025 was analyzed retrospectively for frequency and type of TCMR, impact on kidney function, and graft loss. Potential risk factors for TCMR were evaluated. Results: The cumulative incidence of acute TCMR in the group without pretransplant donor-specific anti-human leukocyte antigen (HLA) antibodies (preDSA) ( Conclusion: An immune suppressive regime of anti-CD25 induction and tacrolimus or MMF or prednisone maintenance is associated with a low risk of TCMR-related graft loss except for recipients with preDSA against HLA class II.

Indexed as

donor-specific antibodiesgraft survivalkidneyrejectionT-cell-mediated rejectiontransplantation

Identifiers

PMID42170034
PMCPMC13187526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.